Maresyl (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. When applied to the nasal mucosa, it stimulates alpha receptors on blood‑vessel smooth muscle, causing vasoconstriction, which reduces swelling and opens the airway for easier breathing.

The appropriate dose of Maresyl is determined by a qualified healthcare professional. Typically, a few sprays per nostril are used, but the exact number and frequency should follow the prescriber’s instructions and the product label.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant or breastfeeding should discuss potential risks with their physician before using Maresyl.

To order Maresyl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maresyl’s active ingredient, Xylometazoline, belongs to the imidazoline class, offering rapid vasoconstriction with a relatively low systemic absorption compared with some phenylephrine‑based sprays. This profile often results in fewer systemic side effects, though all decongestants share a risk of rebound congestion if used beyond recommended duration.

Maresyl should be stored at room temperature, away from excessive heat or direct sunlight. Keep the spray bottle tightly closed when not in use and retain it in its original packaging to protect against moisture.

Maresyl is administered as a nasal spray. The user tilts the head slightly forward, inserts the nozzle into a nostril, and gently presses the actuator to deliver the recommended number of sprays. The process is then repeated in the other nostril if directed by the prescriber.

Serious risks include rebound nasal congestion (rhinitis medicamentosa) after prolonged use, severe hypertension, allergic reactions such as rash or swelling, and rare nasal ulceration. Patients should discontinue use and seek medical advice if any of these events occur.

Maresyl should be avoided by individuals with known hypersensitivity to Xylometazoline or any formulation component, patients with uncontrolled severe hypertension, and children under the age recommended on the label (often under 2 years) unless a healthcare professional advises otherwise.